Current approaches and future strategies for pancreatic carcinoma (Q33929472)

30 July 2017

1 reference

title

Current approaches and future strategies for pancreatic carcinoma (English)

1 reference

30 July 2017

1 reference

Wolff RA

1

1 reference

30 July 2017

Chiao P

2

1 reference

30 July 2017

Lenzi R

3

1 reference

30 July 2017

Pisters PW

4

1 reference

30 July 2017

Lee JE

5

1 reference

30 July 2017

Janjan NA

6

1 reference

30 July 2017

Crane CH

7

1 reference

30 July 2017

Evans DB

8

1 reference

30 July 2017

Abbruzzese JL

9

1 reference

30 July 2017

1 February 2000

1 reference

Investigational New Drugs

30 July 2017

1 reference

30 July 2017

18

1 reference

30 July 2017

1

1 reference

30 July 2017

43-56

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006383831045

30 July 2017

0 references

cites work

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

12 December 2020

Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

1 reference

12 December 2020

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1 reference

12 December 2020

Differential effects of monoterpenes and lovastatin on RAS processing

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma

1 reference

12 December 2020

Cancer metastasis: a search for therapeutic inhibition

1 reference

12 December 2020

Cancer statistics, 1999.

1 reference

12 December 2020

The pharmacokinetics of TNP-470, a new angiogenesis inhibitor

1 reference

12 December 2020

Expression and potential role of E-cadherin in pancreatic carcinoma

1 reference

12 December 2020

Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene

1 reference

12 December 2020

Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma

1 reference

12 December 2020

Mechanistic analysis of pancreatic ductal carcinogenesis in hamsters.

1 reference

12 December 2020

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

1 reference

12 December 2020

Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus.

1 reference

12 December 2020

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

1 reference

12 December 2020

A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

1 reference

12 December 2020

The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization

1 reference

12 December 2020

Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.

1 reference

12 December 2020

Activation of the MAP kinase pathway by the protein kinase raf

1 reference

12 December 2020

Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness

1 reference

12 December 2020

Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study

1 reference

12 December 2020

Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas

1 reference

12 December 2020

Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]

1 reference

12 December 2020

Morphological lesions associated with human primary invasive nonendocrine pancreas cancer

1 reference

12 December 2020

Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group

1 reference

12 December 2020

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

12 December 2020

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

1 reference

12 December 2020

Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue

1 reference

12 December 2020

What is the true rate of K-ras mutation in carcinoma of the pancreas?

1 reference

12 December 2020

p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis

1 reference

12 December 2020

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

1 reference

12 December 2020

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix

1 reference

12 December 2020

DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells

1 reference

12 December 2020

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma

1 reference

12 December 2020

A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer

1 reference

12 December 2020

Rel/NF-kappa B transcription factors and the control of apoptosis

1 reference

12 December 2020

A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor

1 reference

12 December 2020

Phase II study of amonafide in advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol

1 reference

12 December 2020

Crude isolation of DNA from unselected human pancreatic tissue and amplification by the polymerase chain reaction of Ki-ras oncogene to detect point mutations in pancreatic cancer

1 reference

12 December 2020

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

1 reference

12 December 2020

Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.

1 reference

12 December 2020

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

12 December 2020

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors

1 reference

12 December 2020

Overexpression of HER2/neu oncogene in human pancreatic carcinoma

1 reference

12 December 2020

Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms

1 reference

12 December 2020

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head

1 reference

12 December 2020

Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice

1 reference

12 December 2020

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

1 reference

12 December 2020

K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

1 reference

12 December 2020

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer

1 reference

12 December 2020

The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma

1 reference

12 December 2020

An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies

1 reference

12 December 2020

Matrix metalloproteinase inhibitors: present achievements and future prospects

1 reference

12 December 2020

The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines

1 reference

12 December 2020

Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16INK4Mutations

1 reference

12 December 2020

Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma

1 reference

12 December 2020

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

12 December 2020

K-ras mutation in focal proliferative lesions of human pancreas.

1 reference

12 December 2020

Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study

1 reference

12 December 2020

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

1 reference

12 December 2020

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

12 December 2020

Phase I clinical trial of perillyl alcohol administered daily.

1 reference

12 December 2020

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

1 reference

12 December 2020

The preclinical evaluation of angiogenesis inhibitors

1 reference

12 December 2020

Pharmaceutical research in molecular oncology

1 reference

12 December 2020

Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer

1 reference

12 December 2020

Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.

1 reference

12 December 2020

Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells

1 reference

12 December 2020

Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha

1 reference

12 December 2020

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

12 December 2020

The use of chemotherapy in the treatment of advanced gastric and pancreas cancer.

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Role of growth factors in pancreatic cancer.

1 reference

12 December 2020

Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer

1 reference

12 December 2020

Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases

1 reference

12 December 2020

Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression

1 reference

12 December 2020

SMS 201-995 treatment and advanced intestinal cancer: a pilot study.

1 reference

12 December 2020

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

1 reference

12 December 2020

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006383831045

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference